Annual public health and economic benefits of seasonal influenza vaccination: a European estimate

被引:106
作者
Preaud, Emmanuelle [1 ]
Durand, Laure [2 ]
Macabeo, Berengere [2 ]
Farkas, Norbert [3 ]
Sloesen, Brigitte [4 ]
Palache, Abraham [5 ]
Shupo, Francis [6 ]
Samson, Sandrine I. [1 ]
机构
[1] Sanofi Pasteur MSD, F-69367 Lyon, France
[2] Sanofi Pasteur, F-69007 Lyon, France
[3] Novartis Vaccines & Diagnost AG, CH-4056 Basel, Switzerland
[4] GlaxoSmithKline, Rixensart, Belgium
[5] Abbott, NL-1381 CP Weesp, Netherlands
[6] Creativ Ceut Ltd, London SE1 9QQ, England
关键词
Influenza; Public health policy; Vaccines and immunization; Modeling; Epidemiology; COST-EFFECTIVENESS; EXCESS MORTALITY; ENGLAND; BURDEN; NORWAY; IMPACT; UNION;
D O I
10.1186/1471-2458-14-813
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Vaccination is currently the most effective means of preventing influenza infection. Yet evidence of vaccine performance, and the impact and value of seasonal influenza vaccination across risk groups and between seasons, continue to generate much discussion. Moreover, vaccination coverage is below recommended levels. Methods: A model was generated to assess the annual public health benefits and economic importance of influenza vaccination in 5 WHO recommended vaccination target groups (children 6 - 23 months of age; persons with underlying chronic health conditions; pregnant women; health care workers; and, the elderly, 65 years of age) in 27 countries of the European Union. Model estimations were based on standard calculation methods, conservative assumptions, age-based and country-specific data. Results: Out of approximately 180 million Europeans for whom influenza vaccination is recommended, only about 80 million persons are vaccinated. Seasonal influenza vaccination currently prevents an annual average of between 1.6 million and 2.1 million cases of influenza, 45,300 to 65,600 hospitalizations, and 25,200 to 37,200 deaths. To reach the 75% vaccination coverage target set by the EU Council Recommendation in 2009, an additional 57.4 million person would need to be vaccinated in the elderly and other risk groups. By achieving the 75% target rate set in EU-27 countries, average annual influenza-related events averted would increase from current levels to an additional +1.6 to +1.7 million cases, +23,800 to +31,400 hospitalization, +9,800 to +14,300 deaths, +678,500 to +767,800 physician visits, and +883,800 to +1,015,100 lost days of work yearly. Influenza-related costs averted because of vaccination would increase by an additional +(sic)190 to +(sic)226 million yearly, in vaccination target groups. Conclusions: Full implementation of current influenza vaccination recommendations of 75% vaccination coverage rate (VCR) in Europe by the 2014-2015 influenza season could immediately reduce an important public health and economic burden.
引用
收藏
页数:12
相关论文
共 50 条
[41]   Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination in Children [J].
Fleming, Douglas M. ;
Elliot, Alex J. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (11) :S154-S158
[42]   Public health unit funding per capita and seasonal influenza vaccination among youth and adults in Ontario, Canada in 2013/2014 and 2018/2019 [J].
Chew, Jo Lin ;
Smith, Brendan T. ;
Buchan, Sarah A. ;
Senthilselvan, Ambikaipakan ;
Pabayo, Roman .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2024,
[43]   From the patient perspective: The economic value of seasonal and H1N1 influenza vaccination [J].
Lee, Bruce Y. ;
Bacon, Kristina M. ;
Donohue, Julie M. ;
Wiringa, Ann E. ;
Bailey, Rachel R. ;
Zimmerman, Richard K. .
VACCINE, 2011, 29 (11) :2149-2158
[44]   Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model [J].
Gerlier, L. ;
Lamotte, M. ;
Greneche, S. ;
Lenne, X. ;
Carrat, F. ;
Weil-Olivier, C. ;
Damm, O. ;
Schwehm, M. ;
Eichner, M. .
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (02) :261-276
[45]   Need for a robust public health response to seasonal influenza in India [J].
Krishnan, Anand .
INDIAN JOURNAL OF MEDICAL RESEARCH, 2023, 157 (05) :421-426
[46]   Health and Economic Benefits of Early Vaccination and Nonpharmaceutical Interventions for a Human Influenza A (H7N9) Pandemic [J].
Khazeni, Nayer ;
Hutton, David W. ;
Collins, Cassandra I. F. ;
Garber, Alan M. ;
Owens, Douglas K. .
ANNALS OF INTERNAL MEDICINE, 2014, 160 (10) :684-+
[47]   School-Based Influenza Vaccination: Health and Economic Impact of Maine's 2009 Influenza Vaccination Program [J].
Basurto-Davila, Ricardo ;
Meltzer, Martin I. ;
Mills, Dora A. ;
Asay, Garrett R. Beeler ;
Cho, Bo-Hyun ;
Graitcer, Samuel B. ;
Dube, Nancy L. ;
Thompson, Mark G. ;
Patel, Suchita A. ;
Peasah, Samuel K. ;
Ferdinands, Jill M. ;
Gargiullo, Paul ;
Messonnier, Mark ;
Shay, David K. .
HEALTH SERVICES RESEARCH, 2017, 52 :2307-2330
[48]   Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States [J].
Net, Pierre ;
Colrat, Florian ;
Costa, Mafalda Nascimento ;
Bianic, Florence ;
Thommes, Edward ;
Alvarez, Fabian P. .
VACCINE, 2021, 39 :A56-A69
[49]   The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China [J].
Ronald Caldwell ;
Craig S. Roberts ;
Zhijie An ;
Chieh-I Chen ;
Bruce Wang .
BMC Infectious Diseases, 15
[50]   Seasonal Influenza Vaccination of Healthy Working-Age Adults A Review of Economic Evaluations [J].
Gatwood, Justin ;
Meltzer, Martin I. ;
Messonnier, Mark ;
Ortega-Sanchez, Ismael R. ;
Balkrishnan, Rajesh ;
Prosser, Lisa A. .
DRUGS, 2012, 72 (01) :35-48